SPATC1L

Across TCGA pan-cancer cohorts, SPATC1L RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SPATC1L’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SPATC1L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SPATC1L is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

LIHC, LUAD, and LUSC are the cancer types where SPATC1L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPATC1L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+2.176	<.001	9	view →
LUAD	All	All	+0.585	<.001	7	view →
LUSC	All	All	+0.769	<.001	6	view →
HNSC	All	All	+0.619	.008	4	view →
BRCA	All	All	+0.476	<.001	4	view →
CHOL	Female	All	+2.983	<.001	3	view →
KICH	All	All	−1.116	.002	2	view →
UCEC	All	All	+0.656	.010	2	view →
BLCA	All	All	+0.645	.044	2	view →
PAAD	Female	All	+0.414	.016	2	view →
KIRC	All	All	+0.331	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SPATC1L–LIHC

Open the LIHC breakdown →